《2020年NCCN肝胆肿瘤临床实践指南(V1版)》胆管癌诊治进展解读

The interpretation of development on diagnosis and management of cholangiocarcinoma:focus on the update of NCCN Clinical Practice Guidelines in Hepatobiliary Cancers(Version 1.2020)

胆管癌是起源于胆管上皮的恶性肿瘤,美国NCCN指南2020年V1版胆管癌更新内容主要包括对第8版AJCC分期进行解释说明,进一步强调对肝内胆管癌的肝门部淋巴结清扫,强调对不可手术切除患者进行系统治疗,辅助治疗方案更加规范,推荐对于晚期胆管癌进行MSI/dMMR检测和基因检测。本文就NCCN指南更新版胆管癌诊治进展做一解读,同时对指南中未讨论的部分加以补充说明。

Cholangiocarcinoma is the malignancy that originates from the epithelium of the bile duct.The update of the version1.2020 of the NCCN Guideline in the United States includes:①The guideline further explained the 8th edition of AJCC staging system.②The guideline further emphasized the need for lymphadenectomy in porta hepatis for patients with intrahepatic cholangiocarcinoma.③Systematic treatment was emphasized in unresectable patients.④Adjuvant treatment was more standardized.⑤It was recommended to carry out MSI/dMMR testing and gene testing for advanced cholangiocarcinoma.The progress of the diagnosis and treatment of cholangiocarcinoma in the updated version of the NCCN guide were interpretated in this paper,and some undiscussed part of the guideline were supplemented.